Drugs Denosumab and odanacatib named it, is the result of clinical trials conducted in Montreal at the annual meeting of the American Society for Bone and Mineral Research, showed that the drug can increase bone mineral density in postmenopausal women with osteoporosis.
Denosumab and odanacatib is the most recent osteoporosis drug that is expected to cure osteoporosis aaccording to Susan Bukata, MD, an orthopedic surgeon from the University of Rochester's Center for Bone Health. "This is a new breakthrough. And this is also a step towards the biological treatment of osteoporosis," said Susan.
Denosumab and odanacatib are two biologic drugs that target osteoclast are bone destructive cells to make new bone. Your bones will continue to evolve, they will continue to evolve constantly, and osteoclast will damage the joints, other cells called osteoblasts, which is a bone builder.
The basic idea behind osteoporosis drugs is to rebalance bone loss (bone loss) and bone growth (bone building) that pass through two earlier treatments.
Denosumab is a monoclonal antibody given by injection (injection) twice a year. The target of this drug is by attacking elements of clams called RANK ligand, which osteoclast need to perform their duties chemical element that is damaging the bone.
Meanwhile odanacatib have different biological tactics. He was attacked by an enzyme called carhepsin K with the aim to reduce osteoclast activity. But for both these drugs are still in the subsequent experiments to better ensure these medicines work better.
No comments:
Post a Comment